CNBX Pharmaceuticals Inc. (OTCMKTS:CNBX – Get Free Report) was the recipient of a large decline in short interest in the month of September. As of September 15th, there was short interest totaling 100,001 shares, a decline of 87.3% from the August 31st total of 788,894 shares. Based on an average daily volume of 10,440,031 shares, the short-interest ratio is presently 0.0 days.
CNBX Pharmaceuticals Stock Performance
Shares of CNBX remained flat at $0.00 during mid-day trading on Friday. 510,000 shares of the stock traded hands, compared to its average volume of 25,917,707. CNBX Pharmaceuticals has a 12 month low of $0.00 and a 12 month high of $0.00.
CNBX Pharmaceuticals Company Profile
CNBX Pharmaceuticals Corp. is a biotechnology company focused on researching cannabinoid-based approaches to cancer treatment and personalized medicine. The company’s work centers on evaluating how cannabinoids and cannabis-derived compounds may affect cancer cells.
CNBX has developed a proprietary cannabinoid research and screening platform designed to test cannabis formulations against patient-derived cancer cells. The platform is intended to support the identification of potentially effective cannabinoid combinations and help researchers study individualized treatment options.
The company’s activities have primarily involved research and development rather than the sale of an established commercial pharmaceutical product.
See Also
- Five stocks we like better than CNBX Pharmaceuticals
- Cracker Barrel Stock Is Rallying Again, But the Turnaround Still Has a Traffic Problem
- Oracle’s Force Majeure Notice Exposes a Bigger Problem for the AI Build-Out
- Oil May Be Stronger Than It Looks—And Diamondback Is on Sale
- BlackBerry Shifts Gears With Coretura Deal
Receive News & Ratings for CNBX Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CNBX Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
